Skip to main content

GSK Resolves Zantac Cancer Claims

GSK Resolves Zantac Cancer Claims

Introduction

GlaxoSmithKline has recently reached a settlement agreement in California state court with four plaintiffs who had filed lawsuits related to Zantac, a heartburn drug that was recalled in 2019 due to its association with cancer.

The lawsuits alleged that the use of Zantac, which contained the unstable active pharmaceutical ingredient ranitidine, resulted in the development of cancer, particularly due to the presence of the carcinogenic chemical byproduct N-Nitrosodimethylamine (NDMA).

Over the past four years, various companies, including GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Sanofi, and others involved in the sale of both brand name and generic ranitidine pills, have faced legal actions from individuals who claim to have been diagnosed with cancer and other injuries linked to NDMA exposure.

Initially, most of the litigation was consolidated in the federal court system, with all Zantac cancer lawsuits centralized in the U.S. District Court for the Southern District of Florida for coordinated discovery and pretrial proceedings. However, a controversial ruling issued by the judge last year excluded all plaintiffs' expert witnesses from testifying at trial, making it challenging for federal plaintiffs to prove that Zantac caused their cancer. This led to the dismissal of all Zantac lawsuits pending in the federal court system.

It is important to note that this federal ruling does not affect Zantac lawsuits filed in California and other state courts, where different standards for the admissibility of expert witness testimony are applied. Therefore, cases in state courts continue to address the allegations brought forth by Zantac users who claim that the drug led to their cancer diagnoses.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!